Premium
Glypican‐3 antibodies: A new therapeutic target for liver cancer
Author(s) -
Feng Mingqian,
Ho Mitchell
Publication year - 2014
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2013.10.002
Subject(s) - glypican 3 , antibody , cancer , hepatocellular carcinoma , medicine , humanized antibody , liver cancer , cancer research , humanized mouse , immunology , monoclonal antibody , immune system
Glypican‐3 (GPC3) is an emerging therapeutic target in hepatocellular carcinoma (HCC), even though the biological function of GPC3 remains elusive. Currently human (MDX‐1414 and HN3) and humanized mouse (GC33 and YP7) antibodies that target GPC3 for HCC treatment are under different stages of preclinical or clinical development. Humanized mouse antibody GC33 is being evaluated in a phase II clinical trial. Human antibodies MDX‐1414 and HN3 are under different stages of preclinical evaluation. Here, we summarize current evidence for GPC3 as a new target in liver cancer, discuss both its oncogenic function and its mode of actions for current antibodies, and evaluate potential challenges for GPC3‐targeted anti‐cancer therapies.